Organon & Co. (NYSE:OGN) Stock Position Boosted by Quest Partners LLC

Quest Partners LLC boosted its stake in Organon & Co. (NYSE:OGN) by 456.0% in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 10,070 shares of the company’s stock after buying an additional 8,259 shares during the period. Quest Partners LLC’s holdings in Organon & Co. were worth $208,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of OGN. Prevail Innovative Wealth Advisors LLC acquired a new stake in Organon & Co. in the 4th quarter valued at about $3,336,000. Cantor Fitzgerald Investment Advisors L.P. acquired a new stake in Organon & Co. in the 4th quarter valued at about $1,850,000. Susquehanna Fundamental Investments LLC acquired a new stake in Organon & Co. in the 1st quarter valued at about $6,284,000. Friedenthal Financial acquired a new stake in Organon & Co. in the 2nd quarter valued at about $769,000. Finally, Allianz Asset Management GmbH lifted its holdings in Organon & Co. by 156.5% in the 4th quarter. Allianz Asset Management GmbH now owns 1,900,554 shares of the company’s stock valued at $27,406,000 after acquiring an additional 1,159,519 shares during the last quarter. Institutional investors own 77.43% of the company’s stock.

Organon & Co. Price Performance

OGN stock opened at $20.47 on Monday. The company has a current ratio of 1.64, a quick ratio of 1.17 and a debt-to-equity ratio of 60.05. Organon & Co. has a one year low of $10.84 and a one year high of $23.10. The firm has a market capitalization of $5.26 billion, a PE ratio of 5.00, a P/E/G ratio of 0.89 and a beta of 0.85. The firm has a 50-day moving average of $21.02 and a two-hundred day moving average of $20.03.

Organon & Co. (NYSE:OGN) last posted its quarterly earnings data on Tuesday, August 6th. The company reported $1.12 EPS for the quarter, beating analysts’ consensus estimates of $1.08 by $0.04. Organon & Co. had a net margin of 15.76% and a negative return on equity of 840.29%. The company had revenue of $1.61 billion during the quarter, compared to analyst estimates of $1.61 billion. During the same period in the prior year, the firm earned $1.31 earnings per share. The business’s quarterly revenue was down .1% on a year-over-year basis. On average, analysts forecast that Organon & Co. will post 4.14 earnings per share for the current year.

Organon & Co. Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Thursday, September 12th. Shareholders of record on Friday, August 16th were paid a dividend of $0.28 per share. This represents a $1.12 dividend on an annualized basis and a yield of 5.47%. The ex-dividend date was Friday, August 16th. Organon & Co.’s dividend payout ratio is presently 27.38%.

Wall Street Analysts Forecast Growth

Separately, JPMorgan Chase & Co. downgraded shares of Organon & Co. from a “neutral” rating to an “underweight” rating and upped their price target for the company from $18.00 to $20.00 in a report on Friday, September 6th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and two have given a buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $22.17.

Organon & Co. Company Profile

Organon & Co develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage.